FierceBiotech 2025-12-23 Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
FierceBiotech 2025-12-22 BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement
FierceBiotech 2025-12-22 Boehringer spells out a $448M future for Rectify's ABC kidney disease program
FierceBiotech 2025-12-22 Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat
FierceBiotech 2025-12-22 AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism
FierceBiotech 2025-12-20 Looking ahead with BD’s Bilal Muhsin on what good AI can still do for healthcare
FierceBiotech 2025-12-19 Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners
FierceBiotech 2025-12-19 Galapagos ends turbulent year with mixed results for last remaining immunology asset